JPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00
JPMorgan Chase & Co. has lowered its price target for Olema Pharmaceuticals (NASDAQ:OLMA) from $30.00 to $28.00 while maintaining an "overweight" rating. Other brokerages have also provided mixed ratings, with HC Wainwright setting a $30.00 target and Oppenheimer reducing theirs to $25.00. Olema's stock opened at $4.20, with a market cap of $287 million. The company reported a quarterly EPS of ($0.51), beating estimates. Insider activity includes Bain Capital Life Sciences purchasing 300,000 shares, increasing their stake by 4%.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) had its price objective reduced by JPMorgan Chase & Co. from $30.00 to $28.00 in a report released on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock.
Get Olema Pharmaceuticals alerts:
Several other brokerages have also issued reports on OLMA. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. Oppenheimer restated an "outperform" rating and set a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.
View Our Latest Stock Report on Olema Pharmaceuticals
Olema Pharmaceuticals Price Performance
Shares of OLMA stock opened at $4.20 on Friday. The stock has a market capitalization of $287.00 million, a PE ratio of -1.92 and a beta of 2.11. The business's 50 day simple moving average is $5.02 and its 200 day simple moving average is $8.14. Olema Pharmaceuticals has a one year low of $3.93 and a one year high of $16.62.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. As a group, research analysts expect that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.
Insider Activity at Olema Pharmaceuticals
In related news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the purchase, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is owned by insiders.
Hedge Funds Weigh In On Olema Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at $163,000. Charles Schwab Investment Management Inc. raised its stake in Olema Pharmaceuticals by 168.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company's stock valued at $3,949,000 after acquiring an additional 207,565 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Olema Pharmaceuticals in the 3rd quarter valued at about $238,000. Portland Investment Counsel Inc. purchased a new stake in Olema Pharmaceuticals during the third quarter valued at about $143,000. Finally, Ikarian Capital LLC bought a new position in Olema Pharmaceuticals during the third quarter worth about $1,098,000. 91.78% of the stock is owned by institutional investors.
Olema Pharmaceuticals Company Profile
(Get Free Report)Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
See Also
- Five stocks we like better than Olema Pharmaceuticals
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
- Breakout Stocks: What They Are and How to Identify Them
- Joby Aviation Stock: Analyst Confidence and Smart Money Align
- How to Invest in Small Cap Stocks
- 3 Momentum Stocks Near 52-Week Highs to Watch for More Growth
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Olema Pharmaceuticals Right Now?
Before you consider Olema Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.
While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here